Compare ALNT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | ZYME |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1995 | 2022 |
| Metric | ALNT | ZYME |
|---|---|---|
| Price | $88.82 | $24.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $64.50 | $38.90 |
| AVG Volume (30 Days) | 292.3K | ★ 596.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 67.09 | 33.33 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $554,478,000.00 | $105,965,000.00 |
| Revenue This Year | $7.53 | $183.10 |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $277.50 | ★ N/A |
| Revenue Growth | 4.62 | ★ 38.87 |
| 52 Week Low | $36.85 | $11.86 |
| 52 Week High | $104.65 | $29.75 |
| Indicator | ALNT | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 48.59 |
| Support Level | $81.21 | $24.79 |
| Resistance Level | $104.65 | $27.15 |
| Average True Range (ATR) | 5.86 | 1.28 |
| MACD | -1.68 | 0.05 |
| Stochastic Oscillator | 36.37 | 52.55 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.